Arbutus Biopharma Corp (ABUS) - 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing treatments for chronic hepatitis B (cHBV). The company's primary assets are its RNAi therapeutic imdusiran (AB-729) and its oral PD-L1 inhibitor AB-101. During 2025, the company underwent significant restructuring, including a 57% workforce reduction, the exit of its corporate headquarters, and the termination of its strategic partnership with Qilu Pharmaceutical to regain global rights to imdusiran.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $14.1 million | $6.2 million |
| Net Loss | $(33.5) million | $(69.9) million |
| Loss Per Share (Basic & Diluted) | $(0.17) | $(0.38) |
| Operating Expenses | $52.2 million | $82.5 million |
| Cash, Cash Equivalents & Investments | $91.5 million | $122.6 million |
| Net Cash Used in Operating Activities | $(39.6) million | $(64.9) million |
| Debt | $0 | $0 |
Note: Revenue increased primarily due to the recognition of $10.4 million in previously deferred revenue from the terminated Qilu agreement. Operating expenses decreased significantly due to restructuring and reduced R&D activities.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 128% year-over-year, driven by the acceleration of revenue recognition from the Qilu partnership termination ($10.4 million) and a $0.5 million milestone from Alnylam. This was partially offset by a decline in ONPATTRO royalties due to cannibalization by Alnylam's newer product, AMVUTTRA.
- Reduced Burn Rate: Net loss improved by 52% to $33.5 million. Operating expenses dropped 37% to $52.2 million, largely due to a $12.9 million restructuring charge (severance, lease impairments) and a $28.8 million reduction in R&D expenses after ceasing discovery efforts and halting the IM-PROVE III trial.
- Liquidity Position: Total cash and investments decreased to $91.5 million from $122.6 million, reflecting a net cash outflow from operations of $39.6 million, though this burn rate is significantly lower than the $64.9 million in 2024.
Guidance, Outlook, and Material Events
- Moderna Settlement (Subsequent Event): On March 3, 2026, Arbutus and its affiliate Genevant entered a settlement agreement with Moderna regarding LNP patent litigation.
- Noncontingent Payment: Moderna will pay an aggregate $950.0 million to Arbutus and Genevant by July 8, 2026. Arbutus is entitled to 20% of this amount (after litigation costs) plus its 16% equity interest in Genevant.
- Contingent Payment: An additional $1.3 billion is payable if Arbutus/Genevant wins a limited appeal regarding 28 U.S.C. §1498. This payment is subject to potential repayment if the appeal is overturned.
- Capital Return: Management is evaluating a return of capital to shareholders in Q3 2026 following receipt of the noncontingent settlement proceeds.
- Pipeline Progress:
- Imdusiran: Phase 2a data showed 47% of patients achieved functional cure or remained off nucleos(t)ide analogue therapy. The company is refining Phase 2b designs.
- AB-101: Phase 1a/1b data showed high receptor occupancy and good tolerability. However, the FDA placed a clinical hold on the AB-101 IND in 2023, which remains unresolved as of the filing date.
- Risks: The company faces risks related to the uncertainty of the contingent settlement payment, the outcome of ongoing litigation against Pfizer/BioNTech, and the potential inability to lift the FDA clinical hold on AB-101.
Investor Verification Checklist
- Settlement Timing: Verify the exact date of receipt for the $950 million noncontingent payment (expected by July 8, 2026) and the specific terms regarding Arbutus's 20% share versus Genevant's share.
- Contingent Payment Conditions: Review the specific legal criteria for the $1.3 billion contingent payment and the likelihood of the §1498 appeal outcome.
- AB-101 Clinical Hold: Confirm the current status of the FDA clinical hold on AB-101 and any correspondence regarding its resolution.
- Capital Return Plan: Monitor announcements regarding the proposed return of capital to shareholders in Q3 2026 to determine if it will be a dividend or share repurchase.
- Qilu Termination Accounting: Confirm that the $10.4 million revenue recognized from the Qilu termination is fully realized and that no future obligations remain under that agreement.